The majority of human cervical cancers are associated with the high-risk human papillomavirus (HPV) types. In mouse models for HPV-associated cancers, estrogen is required for the development of cervical and vaginal cancers. The estrogen receptor ␣ (ER␣) also is required in mice for these cancers to arise. These data are consistent with the observation in women that long-term use of oral contraceptives or multiple pregnancies significantly increases the risk for cervical cancer in HPV-positive women. In the present study, we examined whether drugs that interfere with the function of ER␣ are effective in treating and/or preventing cervical cancer in mice. We provide evidence that a complete ER antagonist, ICI 182,780 (ICI), as well as a selective ER modulator, raloxifene, efficiently clear cancer and its precursor lesions in both the cervix and the vagina. Furthermore, ICI was capable of preventing the onset of cancers in mice bearing precursor lesions. These findings point to the potential value of ER antagonists in controlling gynecological disease in the lower reproductive tracts in women. cervix ͉ papillomavirus ͉ SERM H igh-risk human papillomavirus (HPV) types, particularly HPV16, are causally associated with human malignancies, including cervical and vaginal cancers in women (1). New prophylactic HPV vaccines can prevent infections by a subset of these HPVs; however, they will not eliminate preexisting HPV infections, new infections by high-risk HPVs not targeted by the vaccines, or cervical cancers and precancerous lesions that arise from those HPV infections (2). Traditional therapeutic approaches (i.e., surgery, radiotherapy, and chemotherapy) are of limited value to patients with advanced or recurrent cervical cancer. Consequently, cervical cancer remains the second leading cause of death by cancer among women worldwide (1, 2). New, more effective therapeutic strategies are clearly needed. This preclinical study identifies a potent new therapeutic approach that not only effectively treats preexisting cervical and vaginal cancers but also can prevent their onset in a mouse model for HPV-associated cervical carcinogenesis.The uterine cervix is highly responsive to steroidal hormones, such as estrogen. Correspondingly, cervical cancers most commonly arise in the third to fifth decade (i.e., premenopausal period) of life in women (3). Furthermore, use of oral contraceptives or high parity has been shown to significantly increase the risk for cervical cancer in HPV-infected women (4, 5). These observations raise the possibility that steroidal hormones, such as estrogen, might affect cancers of the cervix, much like that of other hormonally responsive female organs (3, 6). Estrogen replacement therapy alone, however, does not increase the risk for cervical cancer, and tamoxifen, a well-known estrogen receptor (ER) antagonist in breast, has no beneficial effect on cervical cancer (7,8). Unfortunately, neither of these studies controlled for infections with high-risk HPVs that are prerequisite for cervical can...